Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio

Roche announced it will present pivotal Phase III data at ESMO 2026 demonstrating divarasib's superiority over first-generation KRAS G12C inhibitors in lung cancer, giredestrant's improved efficacy without compromising quality of life in breast cancer, and Tam-Peli's robust efficacy in nasopharyngeal carcinoma. These presentations highlight advances across Roche's oncology pipeline with potential to establish new standards of care across multiple cancer types.